Cat. #161793
C2.1 cell line
Cat. #: 161793
Availability: 8-10 weeks
Organism: Human
Tissue: Skin
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Christoper Stipp
Institute: University Of Iowa Research Foundation
Primary Citation: Feddersen et al.2019. Cancer Res. 79(19). PMID: 31416845
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: C2.1 cell line
- Alternate name: C2.1
- Cancer: Skin cancer
- Research fields: Cancer;Drug development
- Parental cell: A375 Melanoma (ATCC)
- Organism: Human
- Gender: Female
- Tissue: Skin
- Donor: A375 (ATCC) -human melanoma cell line of a solid tumor from a 54-year-old female.
- Morphology: Compact Morphology
- Description: Spontaneous vemurafenib resistant A375 Melanoma Clones. Shows frequent alterations of BRAF^V600 protein along with the expression of a truncated BRAF^V600E protein due to a aberrant splice event between exons 1 and 11 in the clone. No increased VAV1 protein levels. Increased MEK Phosphorylation on S298 (Pak Site).
- Production details: Long-term cultures of A375 cells in 3 ?M vemurafenib. Spontaneous vemurafenib-resistant clones and populations were created after 23 and 46 weeks cultured in 3 mm vemurafenib. Maintained in media with 3 mm vemurafenib.
Handling
- Growth medium: DMEM(Gibco) suplemented with penicillin/streptomycin (Gibco) and 10% FBS (Gibco).
References
- Feddersen et al.2019. Cancer Res. 79(19).PMID: 31416844
- Zhu et al. 2022. npj Precis. Onc. PMID: 36271143
